Alzheimer's

Alzheimer's Disease & Dementia: Understanding Symptoms, Diagnosis & Treatment

Alzheimer's disease is the most common cause of dementia, accounting for 60–80% of all dementia cases. It is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques and tau tangles in the brain, leading to the irreversible loss of cognitive function, memory, and the ability to perform daily activities. More than just memory loss, Alzheimer's profoundly affects judgment, orientation, language, mood, and behavior—changes that impact not only the person diagnosed but also their family members and caregivers. At KwikPsych in Austin, we provide comprehensive psychiatric evaluation, behavioral management, and caregiver support for individuals and families navigating Alzheimer's disease.

What is Alzheimer's Disease?

Alzheimer's disease is classified as a major neurocognitive disorder due to Alzheimer pathology in the DSM-5. It is a progressive, irreversible brain disease that slowly damages neurons, leading to cognitive decline and loss of independence. The disease typically begins with mild memory lapses and progresses to severe dementia in which individuals lose the ability to recognize family members, communicate, or care for themselves.

The neuropathology of Alzheimer's involves two key hallmarks:

Amyloid-Beta Plaques: Accumulation of amyloid-beta protein outside neurons, which disrupts cell-to-cell communication and triggers inflammation.

Tau Tangles: Accumulation of tau protein inside neurons, which causes cellular dysfunction and neuronal death.

These pathological changes begin years before cognitive symptoms appear, making early detection and intervention critical. The disease progresses along a continuum: asymptomatic preclinical stage → mild cognitive impairment (MCI) → mild dementia → moderate dementia → severe dementia.

Stages of Alzheimer's Disease

Understanding the stages of Alzheimer's helps patients and families anticipate changes and plan care accordingly.

Preclinical (Asymptomatic) Stage

No cognitive symptoms are present, but amyloid and tau begin accumulating in the brain. This stage may last years or decades. Biomarkers (PET imaging, cerebrospinal fluid analysis, blood tests) can detect pathological changes, but cognitive testing remains normal.

Mild Cognitive Impairment (MCI)

Early-stage memory loss, difficulty with complex tasks, or mild executive function decline. MCI represents a clinical intermediate state between normal aging and dementia. Individuals are still independent but may notice subtle changes that concern them or their loved ones. Approximately 10–15% of people with MCI progress to dementia each year.

Mild Dementia

Memory loss becomes more noticeable. Individuals may struggle with orientation to time and place, forget recent conversations or events, have difficulty with complex tasks, become repetitive or lose track of objects. Language and mood changes may emerge. Despite these changes, individuals can still perform basic activities of daily living with assistance.

Moderate Dementia

Cognitive and behavioral symptoms intensify. Memory loss extends to long-term memories and familiar people. Significant behavioral changes emerge: agitation, aggression, wandering, sleep disturbances, paranoia, or hallucinations. Personality changes occur. Assistance with basic self-care (bathing, dressing, toileting) becomes necessary.

Severe Dementia

Loss of communication ability, loss of physical control, loss of awareness of surroundings. Constant care is required. The person requires help with all basic functions and may be bedbound or minimally mobile.

Symptoms of Alzheimer's Disease

Early symptoms often begin with memory loss but expand to affect multiple cognitive domains:

Memory Loss

• Forgetting recent events, names, or appointments
• Repetitive questions or conversations
• Misplacing objects
• Difficulty following conversations or instructions

Executive Function & Problem-Solving

• Difficulty managing finances or medications
• Poor judgment in financial or social decisions
• Difficulty planning complex activities

Orientation & Navigation

• Getting lost in familiar places
• Confusion about time, date, or place
• Difficulty recognizing familiar people or places

Language & Communication

• Difficulty finding words (anomia)
• Decreased vocabulary or word substitution
• Difficulty following or participating in conversation
• Repetitive speech

Visuospatial Skills

• Difficulty interpreting visual information
• Problems with depth perception or spatial awareness
• Difficulty reading, writing, or drawing

Behavioral & Mood Symptoms

• Depression and withdrawal
• Anxiety, irritability, or emotional outbursts
• Apathy or loss of initiative
• Aggression or agitation
• Personality changes (preexisting traits may become exaggerated)
• Sleep disturbances, including sundowning (increased confusion in evening hours)
• Hallucinations or delusions (in 20–30% of patients)

Risk Factors & Causes

Alzheimer's disease results from the complex interplay of genetic, lifestyle, and environmental factors.

Non-Modifiable Risk Factors

• Age: Incidence increases significantly after age 65; doubles every 5 years after age 65
• Genetics: Family history of dementia increases risk; APOE4 gene carriers have elevated risk
• Biological Sex: Women account for approximately two-thirds of Alzheimer's cases, partly due to longer life expectancy

Modifiable Risk Factors

• Cardiovascular disease and hypertension
• Diabetes
• Obesity
• Cognitive inactivity (lack of mental stimulation)
• Social isolation
• Sleep disturbances
• Traumatic brain injury with loss of consciousness
• Chronic depression
• Smoking and alcohol abuse
• Physical inactivity

Protective Factors

• Cognitive engagement and lifelong learning
• Regular physical exercise
• Mediterranean diet or similar heart-healthy eating patterns
• Strong social connections
• Cognitive reserve from higher education or intellectually demanding work

How Alzheimer's is Diagnosed

Diagnosis requires a comprehensive evaluation including clinical history, cognitive testing, laboratory studies, and neuroimaging.

Clinical Evaluation

• Detailed history from patient and informant (family member or caregiver)
• Assessment of onset and progression of cognitive symptoms
• Review of family history, medical history, medications, and lifestyle factors
• Mental status examination assessing memory, language, executive function, and visuospatial skills

Cognitive Testing

• MMSE (Mini-Cog and Montreal Cognitive Assessment (MoCA): Quick screening tools
• Neuropsychological Testing: Comprehensive evaluation of cognitive domains (memory, language, executive function, visuospatial skills) by a trained neuropsychologist

Laboratory & Imaging

• Blood work: Vitamin B12, folate, thyroid function, glucose, kidney and liver function; newer biomarker tests (phosphorylated tau, amyloid-beta ratio)
• MRI or CT: Structural brain imaging to rule out stroke, tumor, normal pressure hydrocephalus, or significant atrophy
• PET Imaging: Positron emission tomography to detect amyloid and tau pathology; increasingly available but not routine

Differential Diagnosis Considerations

Conditions that mimic Alzheimer's and must be ruled out include:

• Vascular dementia
• Lewy body dementia
• Frontotemporal dementia
• Parkinson's disease dementia
• Medication-induced cognitive impairment
• Delirium (acute confusion, often medical)
• Major depression ("pseudodementia")
• Hypothyroidism, B12 deficiency, normal pressure hydrocephalus

How KwikPsych Helps: Psychiatric Management of Alzheimer's

While neurologists and primary care physicians often coordinate the diagnostic workup, psychiatrists play a crucial role in managing the behavioral, mood, and psychiatric complications of Alzheimer's disease. Our psychiatrists at KwikPsych provide:

Cognitive & Neuropsychological Evaluation

• Comprehensive assessment of cognitive function
• Referral for formal neuropsychological testing when indicated
• Coordination with neurologists for biomarker testing and neuroimaging

Medication Management

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) to slow cognitive decline and improve behavioral symptoms
• NMDA receptor antagonists (memantine) for moderate to severe dementia
• Medications to manage behavioral symptoms (anxiety, agitation, aggression, paranoia)
• Careful attention to medication interactions and avoidance of anticholinergics, benzodiazepines, and antipsychotics when possible

Behavioral Management Strategies

• Environmental modifications to enhance safety and reduce triggers for agitation
• Structured daily routines and consistent caregiver approaches
• Communication strategies tailored to cognitive stage
• Management of specific behaviors: wandering, aggression, sexual disinhibition, resistiveness to care

Mood & Psychiatric Symptom Management

• Treatment of depression, anxiety, and apathy
• Management of psychosis (hallucinations, delusions) using atypical antipsychotics at the lowest effective dose
• Evaluation and management of sleep disturbances

Caregiver Support & Family Counseling

• Psychoeducation about disease progression and what to expect
• Grief support and validation of caregiver emotional burden
• Strategies for managing difficult behaviors and reducing caregiver stress
• Coordination with social services, community resources, and support groups
• Psychiatric treatment for caregiver depression and anxiety

Advance Planning & Palliative Care Coordination

• Advance directive and end-of-life care discussions
• Coordination with palliative care and hospice when appropriate
• Support through the transition from curative to comfort-focused care

Treatment Options for Alzheimer's

Pharmacologic Treatment

Cholinesterase Inhibitors

• Donepezil (Aricept): 5–10 mg daily (mild to moderate); up to 23 mg daily (moderate to severe); approved for mild, moderate, and severe AD
• Rivastigmine (Exelon): 1.5–6 mg twice daily (oral) or transdermal patch; approved for mild to moderate Alzheimer's disease and mild to moderate Parkinson's disease dementia
• Galantamine (Razadyne): 8–12 mg twice daily (immediate-release) or 8–24 mg once daily (extended-release); approved for mild to moderate AD

These medications increase acetylcholine availability in the brain, which supports memory and cognitive function. They may slow cognitive decline by 6–12 months but do not stop the disease. Side effects include nausea, vomiting, diarrhea, and bradycardia.

NMDA Receptor Antagonist

• Memantine (Namenda): 5–20 mg daily; approved for moderate to severe AD; may be combined with cholinesterase inhibitors
• Reduces excitotoxicity from excess glutamate; may improve memory, attention, and language
• Better tolerated than cholinesterase inhibitors; side effects include dizziness, constipation, headache

Anti-Amyloid Monoclonal Antibodies (newer options)

• Aducanumab (Aduhelm) and Lecanemab (Leqembi): Emerging treatments targeting amyloid plaques
• Can slow cognitive decline in early stages but require regular infusions and biomarker confirmation
• Risk of amyloid-related imaging abnormalities (ARIA)

Non-Pharmacologic Interventions

• Cognitive Stimulation: Puzzles, reading, learning, engaging hobbies
• Physical Activity: Regular exercise improves mood, sleep, and cognition
• Social Engagement: Meaningful activities, community involvement, social connection
• Structured Routine: Consistency reduces anxiety and behavioral problems
• Sleep Hygiene: Regular sleep schedule, light exposure, activity
• Nutritional Support: Mediterranean or DASH diet; ensure adequate hydration

Living with Alzheimer's: Caregiver Resources

Caring for someone with Alzheimer's disease is emotionally and physically demanding. At KwikPsych, we recognize that caregiver wellbeing is integral to quality care.

Caregiver Challenges

• Emotional burden: grief, guilt, frustration, sadness
• Physical exhaustion and health decline
• Social isolation from caregiving demands
• Financial strain
• Risk of depression, anxiety, and burnout

Caregiver Support

• Individual or family therapy to process grief and stress
• Support groups for Alzheimer's caregivers
• Respite care options
• Community resources and adult day programs
• Consultation on safety modifications, behavioral management, and care planning
• Psychiatric treatment for caregiver mood and anxiety disorders

Why Choose KwikPsych for Alzheimer's Care?

At KwikPsych in Austin, Texas, we provide compassionate, evidence-based psychiatric care for individuals with Alzheimer's disease and their families. Dr. Monika Thangada, MD, and our clinical team understand the neurobiological and behavioral complexity of neurocognitive disorders. We coordinate care with neurologists, primary care physicians, and other specialists to provide integrated assessment and management. We accept most major insurance carriers and offer flexible telehealth options for patients across Texas.

Our Commitment:

• Comprehensive neuropsychiatric evaluation
• Individualized medication management
• Behavioral interventions and caregiver training
• Family-centered, compassionate care
• Continuity of care through all stages of disease
• Crisis support and end-of-life care planning

If you or a loved one is experiencing memory loss or cognitive changes concerning for Alzheimer's disease, we encourage you to reach out. Early assessment, diagnosis, and treatment can optimize outcomes and quality of life. Contact KwikPsych at 737-367-1230 or visit us at 12335 Hymeadow Dr, Suite 450, Austin, TX 78750. We also offer telehealth appointments throughout Texas. For crisis support, please call the 988 Lifeline.